Laura Sinigaglia

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 232 citations

Medicine, Oncology, Chemotherapy +14

LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial

Jean Bourhis, Yungan Tao, Xiaonan Sun et al. · Annals of Oncology · 2021 · 83 citations

Medicine, Oncology, Radiation Oncology +6

A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN): First results of the GORTEC 2015-01 “PembroRad” trial.

Xu Sun, Christian Sire, Yungan Tao et al. · Journal of Clinical Oncology · 2018 · 53 citations

Medicine, Oncology, Radiation Oncology +14

854MO Avelumab-cetuximab-radiotherapy (RT) versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Final analysis of randomized phase III GORTEC 2017-01 REACH trial

A. Aupérin, Xinzhi Sun, X. Liem et al. · Annals of Oncology · 2024 · 17 citations · Full text

Medicine, Oncology, Radiation Oncology +8

Cetuximab, Docetaxel and Cisplatin as First-Line Treatment in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results of the GORTEC 2014-01 TPExtreme Randomized Trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · SSRN Electronic Journal · 2020 · 13 citations · Full text

Medicine, Oncology, Pharmacotherapy +13